Impact of skeletal muscle loss and sarcopenia on outcomes of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma
Open Access
- 12 September 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 12, 1650337
Abstract
Background: Sarcopenia is a systemic disorder characterized by the progressive loss of skeletal muscle mass and function; however, its impact on the treatment outcomes of patients with esophageal cancer remains inconclusive. We aimed to evaluate the impact of sarcopenia and dynamic changes in skeletal muscle during treatment on neoadjuvant immunochemotherapy (NICT) efficacy and prognosis in patients with locally advanced ESCC.Methods: We retrospectively included 272 patients with locally advanced ESCC who received NICT. We calculated the skeletal muscle index (SMI) and its rate of change (ΔSMI%) from CT images at the L3 vertebral level obtained before and after treatment. Sarcopenia was defined as an SMI < 52.4 cm2/m2 in men and 2/m2 in women, and a ΔSMI% < −2.8% was designated as excessive skeletal muscle loss.Results: The prevalence of sarcopenia increased from 50.9% before treatment to 55.1% at therapy completion. Pre-NICT sarcopenia correlated with tumor progression (p = 0.02) and was associated with a significantly lower pathological complete response (pCR) in patients who had sarcopenia than in those without (14.7% vs. 25.0%, p = 0.04). Patients with tumor progression had a significantly lower SMI than those in the disease-control group (41.6 ± 7.24 vs. 48.71 ± 8.39, p = 0.04). In a subgroup analysis of excessive skeletal muscle loss, these patients experienced higher hematologic toxicity (leukopenia: 33.4% vs. 20.9%, p = 0.04; anemia: 70.7% vs. 50.6%, p = 0.01) and lower pCR rate (12.0% vs. 22.8%, p = 0.05). After a median follow-up of 20.4 months, sarcopenia before or after NICT did not significantly affect overall survival (OS) or disease-free survival (DFS) (p > 0.05). Conversely, excessive skeletal muscle loss during treatment emerged as an independent prognostic factor for OS in multivariate analysis (HR = 0.47; 95% CI, 0.25–0.91; p = 0.03); however, it was not associated with DFS (p = 0.22).Conclusion: Treatment-induced excessive skeletal muscle loss may serve as a predictive marker for NICT toxicity and short-term survival in patients with locally advanced ESCC, highlighting the need for dynamic nutritional monitoring to optimize treatment tolerance.Keywords
This publication has 38 references indexed in Scilit:
- Prehabilitation of Patients With Oesophageal Malignancy Undergoing Peri‐Operative Treatment (Pre‐EMPT): Outcomes From a Prospective Controlled TrialJournal of Surgical Oncology, 2025
- Current status and perspectives of esophageal cancer: a comprehensive reviewCancer Communications, 2024
- Body composition derangements in lung cancer patients treated with first‐line pembrolizumab: A multicentre observational studyJournal of Cachexia, Sarcopenia and Muscle, 2024
- An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinomaCancer Cell, 2023
- The prognostic value of sarcopenia in oesophageal cancer: A systematic review and meta‐analysisJournal of Cachexia, Sarcopenia and Muscle, 2022
- The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patientsJournal of Cachexia, Sarcopenia and Muscle, 2022
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell CarcinomaJAMA, 2021
- Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta‐analysisJournal of Cachexia, Sarcopenia and Muscle, 2021
- Relationship of Peripheral Lymphocyte Subsets and Skeletal Muscle Mass Index in Sarcopenia: A Cross-Sectional StudyThe Journal of nutrition, health and aging, 2020
- Skeletal muscle cells actively shape (auto)immune responsesAutoimmunity Reviews, 2018